Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Outlines Plans to Help With the COVID-19 Outbreak

By Brian Orelli, PhD - Mar 13, 2020 at 6:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharma giant is helping any way it can.

While other drugmakers have been working on treatments and vaccines for COVID-19 for a month or more, Pfizer (PFE 3.00%) finally announced its plan to help with the virus today. As they say, better late than never.

The big pharma is working with BioNTech (BNTX 1.32%) on a potential mRNA vaccine for COVID-19, which is caused by the new coronavirus. The duo could make progress quickly since the only thing that's needed to design an mRNA vaccine is the sequence of the gene, which is already known for the coronavirus that causes COVID-19.

Moderna (MRNA 0.70%) announced in late January that it had started working on an mRNA vaccine for COVID-19, and about a month later, it had shipped its mRNA vaccine mRNA-1273 to the National Institute of Allergy and Infectious Diseases for a clinical trial that's expected to start next month.

Pfizer has created a SWAT team dedicated to address the pandemic and is committed to sharing tools and insights that it discovers in an open-source environment. The company has committed to loaning out its clinical development and regulatory expertise to support smaller biotechs that are developing treatments and vaccines for the disease.

Scientist working in a laboratory

Image source: Getty Images.

The company also committed its manufacturing capabilities for therapies or vaccines that are eventually approved. "As one of the largest manufacturers of vaccines and therapeutics, Pfizer is committed to using any excess manufacturing capacity and to potentially shifting production to support others in rapidly getting these life-saving breakthroughs into the hands of patients as quickly as possible," the company said in a statement.

Perhaps admitting that it was slow to the game, Pfizer also noted that it plans to address future global health threats by "reaching out to federal agencies including NIH, NIAID and CDC to build a cross-industry rapid response team of scientists, clinicians and technicians able to move into action immediately when future epidemics surface."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01
BioNTech SE Stock Quote
BioNTech SE
BNTX
$134.04 (1.32%) $1.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.